Brought to you by 
Novartis licenses Xencor's cancer immunotherapy candidates, XmAb technology
23 May 2022
Executive Summary
Xencor Inc. and Novartis Institutes for BioMedical Research Inc. will jointly collaborate on the development of bispecific antibodies as cancer immunotherapeutics, using Xencor's XmAb antibody engineering platform.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis licenses Xencor's cancer immunotherapy candidates, XmAb technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice